A blood pressure drug is being recalled after a pharmacy alerted the Medicines and Healthcare products Regulatory Agency (MHRA) to a packaging error.
The MHRA said Crescent Pharma Limited has issued a precautionary recall of one batch of Ramipril 5 mg capsules because a “potential manufacturing error” may have resulted in “two blood pressure medicines being packaged incorrectly”.
The recall follows a complaint from a pharmacy whose patient reported that a pack labelled Ramipril 5 mg capsules, batch number GR164099, contained ”blister strips of Amlodipine 5 mg tablets inside the sealed carton”, the regulator added.
Read more: Fake Mounjaro pens supplied through UK online pharmacy
Both blood pressure medications are produced by Crescent Pharma at the same site, it said, and the error “appears to have occurred during secondary packaging of the blister strips into the cartons”.
The MHRA noted that the risk to patients of accidentally substituting “one widely used blood pressure medication for another is low”.
But it advised pharmacy teams to stop supplying the impacted batch “immediately”, “quarantine all remaining stock” and return it to their suppliers.
Read more: Toxin poisoning in 36 children after infant formula recalls
The regulator said that if batch or product traceability information is available, pharmacy and healthcare professionals involved in dispensing drugs “should identify and immediately contact all patients who have been dispensed the impacted product” and confirm whether they “have remaining stock within their possession for return”.
If this information is not available, it added, pharmacists “should identify all patients dispensed this product” between June 6, 2025 and March 6, 2026.
“Where appropriate and feasible, contact all patients who have been dispensed the impacted product with priority given to those who have been dispensed the product most recently and within the last 28 days,” it said.
Read more: MHRA busts second illicit weight loss jab manufacturing facility
“The majority of this was distributed in 2025 and therefore it is expected that many of these packs will have been dispensed to patients and consumed.”
And it added that if any patients are identified with this product, pharmacy and other healthcare professionals involved in dispensing “should also contact the patients’ GP” to “discuss treatment review and if a new prescription is required for ongoing resupply”.
Read more: MHRA issues alert after pharmacy robot spots drug barcode error
It comes after the MHRA revealed last month that falsified versions of Mounjaro pens have been supplied through an online pharmacy in the UK.
And it follows the UK Health Security Agency announcing that some 36 children have been reported as having symptoms of poisoning after infant and follow-on formulas were recalled over potential toxin contaminations.
